THERAPY AGAINST A DISEASE AND/OR PATHOGEN"

Technical field

This application relates to a method of obtaining electromagnetic frequencies for bioresonance therapy and/or in therapeutic frequential solutions against a disease and/or pathogen.

Background art

Since ancient times the human being has been plighted in the search and development of natural products with the objective of being used fundamentally as dietary supplements or medical application, in the fight against bacterial infections, cancer, diabetic, inflammatory, fungal diseases and others with significant effects. Extreme agents and conditions cause very reactive behaviors and actions on the part of living organisms that lead them to produce bioactive compounds for such purposes as intoxications, infections, and survival competition.

Recently, Carrol et al. (2021) described numerous marine natural products found and extracted from the most diverse microorganisms like phytoplankton, zooplankton, and other more developed marine groups exhibiting relevant biological activities. For example, the group of marine and freshwater bivalves includes a large range of classes, families, genera, and species. The primitive characteristics of bivalves connected with high resistance to strong toxic media should be highlighted to better understand their immunological systems. It is known that the mollusks, in general, represents a very ancient phylogenetic group with other primitive aquatic animals originated from Cambric period (MYA) around 540 to 520 million years ago (Campbell and Reece, 2001; Huber, 2010). Furthermore, particularly A. cygnea mollusk, is a freshwater bivalve with a parasitic relationship which is thought to be Triassic in origin around more than 200 million years ago (Pfeiffer et al., 2019; Watters, 2001; Araujo et al., 2018). So, A. cygnea of superfamily Unionacea is a product of a great and explosive species divergence (around 700 species) in brief evolutionary period and also presenting an aggressive ectoparasitic life through temporary larval encystment on the fish hosts to process the larvae metamorphosis until free-living juvenile, at low survival range. All this, added to a further adult living way in a high sulfur and contaminated mud at lagoon bottom to reach on adult bivalve phase, implicates a very hard confront against extreme and hostile natural conditions which in turn leads us to suppose the involvement of a very flexible, agile, functional and resistant immune system.

Bivalves in their natural habitat can manage their homeostasis and survival, under permanent and very aggressive contact, against a wide variety of pathogens as bacteria, virus, toxic compounds, and immunosuppressive factors. In general, it can be said, that these antibacterial, or anti-viral properties, are derived from a set of bioactive compounds or specific metabolites, that prevent the growth of bacteria and/or the reproduction of bacteria and viruses, or even inducing their destruction and allow them to thrive in different aquatic ecosystems (Ng, et al., 2015; Sousa and Mariana, 2020, Gestal et al., 2020) According Mydlarz et al. (2006) and Girdn-Perez (2010) the immune system of invertebrates, such as mollusks consists of innate mechanisms very effective against antigens commonly present in the environment. The bivalve system involves cellular and humoral reactions which operate in a synchronized way (Galloway and Depledge, 2001). The study of Pruzzo et al. (2005) suggests that the circulating hemocytes will accomplish a cellular response with main goal to eliminate microbes through phagocytosis and cytotoxic reactions through lysosomal enzymes and anti-microbial peptides, and the respiratory burst which involves the production of oxygen metabolites, meaning superoxide anion, hydrogen peroxide, and intermediated compounds with high bactericidal activity. Based on Gestal et al. (2020), it is reinforced that the elimination of microorganisms by defense cells in mollusks is a dynamic process that involves integrating synthesis of granule proteins during differentiation, migration onto sites of infection, phagocytosis and killing of microorganisms, modulation of their effector cells, and finally apoptosis. In addition, complementary reactions come from humoral components mainly composed by lectins (beyond mentioned lysosomal enzymes and antimicrobial peptides) described in bivalves as inductor of bacteria agglutination promoting molecular connections between the surface of bacteria and hemocytes for posterior phagocytosis operation (Pruzzo et al., 2005).

Although, it is currently understood and observed in mollusks that an adaptive immune response like vertebrates is not well developed, there are few studies informing some sort of "immunological memory" present in bivalves, generally described as immune priming (Green and Speck, 2018). Several researches revealed to have a different reactions to a secondary exposure to similar bacteria strains, as in scallop Chlamys farreri, inducing a faster and more effective action (Cong, et al., 2009; Wang et al., 2013); an antiviral immune memory, after nucleic acid injections, was also proved in juvenile oysters, maintaining protection against following infections during 5 months (Lafont, et al., 2017); and a maternal transfer of immune protection to offspring against bacterial infections was described in few research works (Yue et al., 2013). On the other hand, it is possible to induce extracellular recognition and effector proteins, such as lectins, peptidoglycan-recognition proteins, thioester bearing proteins, lipopolysaccharide and bl,3-glucan-binding proteins, fibrinogen-related proteins (FREPs) and antimicrobial proteins (Bassem and Raftos, 2015). Therefore, these relevant signs indicate that the immunological system in bivalves eventually present more plasticity than initially thought.

Then, bioactive products, whether naturally produced or induced by stimulation as those in the freshwater bivalves, will form part of an immune system capable of countering the appearance, development of diseases and homeostatic changes in the human body. However, the presence of chemical contaminants in water is a major subject of concern, since many of these molecules are potent immune suppressors in bivalves, even at a low concentration.

The detection and monitoring of electrical properties of acupuncture points were reported in the human body several decades ago by Nakatani, 1956; Niboyet, 1963, Voll, 1975) suggesting that the skin of acupuncture points show unique bio-electrical characteristics, being later reported and confirmed by Michalak and Nawrocka-Bogusz (2011) and Hong (2016). According to Colbert et al., (2008) and later supported by Karakos, et al. (2019), it is possible to emphasize three aspects: (1) acupuncture points and meridians show lower electrical skin resistance and higher capacitance than surrounding tissue. (2) Higher or lower resistance of specific acupuncture points is correlated to certain clinical diseases. (3) Clinical and laboratory data show that experimentally induced physiologic dysfunction and subsequent recovery correlates with an increased or decreased electrical impedance at relevant acupuncture points. Electrical skin impedance of acupuncture points is electrically distinct from non-acupuncture points and that changes in skin impedance of acupuncture points might be significant for diagnostic, therapeutic, and research purposes.

The biggest discovery of electro-acupuncture of Voll (EAV) method is to correlate external bioelectrical points and respective electrical conducts with internal physiologic functions of specific organs, systems, and tissue types (Voll, 1975; Leonhardt HS, 1980; Huong, 2020). Until Voll, these points had been mainly used for diagnostic purposes, as those in Traditional Chinese Medicine. From Voll it was also proposed to evaluate the substances effects on the human body (Cornelissen 2007; Leonhardt, 1980; Sarkova and Sarek, 2005). With Morell ^' s innovation (Morell,1987) it was even possible treatments through the acupoints combining with substances frequencies on new EAV functional pathways as those correlated with Lymphatic, Nervous, Circulatory and endocrine (Allergy) systems, also connected with Joints, Fibroid Tissue, Skin, Cellular Metabolism and other diseases. Curiously, it is very interesting to observe that some of these conducts are deeply implicated in the SARSCoV, MERSCov and Covid-2 diseases when virus infection occurs in the human organism. Moreover, according to Cornelissen theory based on Mora-Diagnosis and Therapy (Cornelissen 2007), it was possible to demonstrate how toxic chemical compounds can clearly disturb the internal body environment producing additional high stressing reaction. Over the years developed a comprehensive systematic test that runs to identify pollutants and allergic compounds calling Mesenchymal Biological Extreme-Stress (MEBES) agents. This becomes increasingly relevant as there are now more than 5 million synthetic chemical substances able to produce a chronic condition in the human diseases. So, the application of a MEBES substance in human body can well simulate the clinical cases where there are one or more comorbidities in simultaneous with the SARS virus-infection. This situation can reflect the several mixed and complex human diseases which can be diagnosed and treated by the bioresonance an equipment such as the Mora®Nova device using bioresonance frequencies from natural bioactive compounds, already existing or previously induced in living organisms such as A. cygnea hemolymph/plasma.

The morphology of the SARS coronavirus is characteristic of the coronavirus family. These viruses have large spherical pleomorphic particles with bulbous surface projections that form a crown around the particles. The virus envelope contains lipids and appears to consist of a distinct pair of dense electron involucres. This virus is a single-stranded positive RNA virus, belonging to a family of coronaviruses. Its genome is about 29.7kb, one of the largest among RNA viruses. (Li et al., 2003). The example for SARSCoV in the present application is based in the fact that this virus presents the original structure, which forms the root of a lineage Coronaviridae family including MERS-CoV and SARS-CoV-2, as group of large RNA viruses that infect many animal species (Le Bert et al., 2020). It is common to observe the ability of a single virus to cause widely differing pathological manifestations in humans. The sequences of selected structural and non- structural proteins are highly conserved among different coronaviruses . This is not surprising, since that the SARS- CoV-2 and SARS-CoV viruses have a homology of about 77.2% and 90.5% in the amino acids that make up protein S and N, respectively. This degree of homology is much less in the case of other coronaviruses (Silva et al., 2020; Guo Li et al. 2020; Okba N et al. 2020). In this context, it is imperative to know if this can induce false positives in serological reactions to SARS-CoV-2 tests.

The resurgence of SARS or new some viral strain of SARSCoV, was possible and the demand for commercial vaccines and therapeutic development remains. However, the cost and duration of product development and uncertain future demand result in unfavorable economic conditions for carrying out this task (Kadioglu et al., 2020).

According to National Cancer Institute, USA, three quarters of drugs for all diseases worldwide during the past half century were in the one way or another based on natural resources (Newman and Cragg, 2010; 2016), which according to Kadioglu et al. (2020) can function as chemical scaffolds being indispensable to develop novel compounds with improved pharmacological features. One simple, expeditious and functional hypothesis, supported by the "Intelligence based medicine", consists of a screening method of electro-biological data from natural compounds by a computerized bioresonance integrator (Voll 1975; Leonhardt HS, 1980; Sarkova and Sarek, 2005 Cornelissen 2007; Hong 2016). This integrator mechanism allows to check and describe physiological role of natural drugs in different human systems. Thus, it will be possible to create a virtual and personalized human model from the collection of functional physiological parameters from various human systems diagnosis and store it in memory in an intelligent integrator. This human virtual model is submitted to specific fluid or liquid interface to evaluate the respective interference from dynamic substances (molecules, antibody, drugs, fluids, plants, etc.) as a therapy effect or, in the contrary, as a toxic influence.

Summary

The present invention relates to a method of obtaining electromagnetic frequencies from aquatic non-human organisms to be used in bioresonance therapy and/or in therapeutic frequential solutions against diseases and/or pathogen infections in human organisms, comprising the following steps:

Obtaining electromagnetic frequencies related to at least one disease and/or at least one pathogen carried out by a bioresonance device;

Obtaining a biological fluid sample from an aquatic non-human organism; Transferring the electromagnetic frequencies related to at least one disease and/or at least one pathogen to the biological fluid sample using the bioresonance device;

Administering the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen to an aquatic non-human organism such as to promote an immune response against the at least one disease and/or at least one pathogen by the aquatic non-human organism;

Obtaining a second sample of biological fluid sample from said aquatic non-human organism administered with the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen;

Obtaining electromagnetic frequencies from the second sample of biological fluid of said non-human organism administered with the electromagnetic frequencies related to at least one disease and/or at least one pathogen using the bioresonance device.

In one embodiment the electromagnetic frequencies obtained in the last step are transferred to a physiological carrier using the bioresonance device.

In one embodiment the sample of biological fluid is obtained from plasma, hemolymph, or blood.

In one embodiment the electromagnetic frequencies related to at least one disease and/or at least one pathogen can be obtained from an electromagnetic frequency database or obtained from a human organism in which the disease and/or the pathogen is present. In one embodiment the aquatic non-human organism is selected from Anodonta cygnea, Anodonta anatine, Unio pictorum, Unio tumidus, Unio crassus , Margaritifera margaritifera, Hyriopsis myersiana, Hyriopsis cumingii, Pseudoanodonta complanate, Sinanodonta woodiana, Corbiculafluminea, Corbicula fluminalis, Corbicula elegans, Corbicula japonica, Corbicula Africana, Crassostrea angulata, Crassostrea gigas, Crassostrea virginica, Mytilus edulis, Mytilus galloprovincialis , Mytilus platensis, Mytilus trossulus, Ruditapes decussatus, Ruditapes variegatus, Ruditapes philipinarum, Pinctada maxima, Pinctada Margaritifera, Pinctada fucata, Pinctada Martensi, Pecten maximus, Pecten jacobeus, Pecten yessoensis, Pecten novaezealandiae, Pectin ravenelim, Pecten tigris, Mugil cephalus, Mugil curema, Mugil brasiliensis , Liza ramada, cyprinus carpio, Oncorhynchus mykiss, Salmo truta, Salmo lacustris, Trachurus trachurus, Trachurus picturatus, Scomber scombrus, Scomber colias, Scomber japonicus, Scomberomorus brasiliensis, Dicentrarchus labrax, Centropomus undecimalis, Solea solea ou solea vulgaris, Solea senegalensis, Platichthys flesus, Paralichthys brasiliensis, Scophthalmus rhombus, Carcinus aestuarii, Carcinus maenas, Scylla serrata, Cancer pagurus, Cancer productus, Cancer bellianus, Procambarus clarkii, Procambarus alleni or other species of Procambarus.

In one embodiment the bioresonance device is selected from MORA device, MoraONova device, Listen Machines, Bicom device, Sensitiv Audit and Imago device or Vega Select Machine .

In one embodiment the disease is selected from cancer, a neuro-development disorder, an auto-immune disease, a neurodegenerative disease, a rare disease, a metabolic disease.

In one embodiment the pathogen is selected from a virus, bacteria, parasite or fungus.

In one embodiment the invention related to the use of the electromagnetic frequencies in bioresonance therapy.

In one embodiment the invention related to the use of the electromagnetic frequencies in therapeutic frequential solutions.

General description

The present invention relates to a method of obtaining electromagnetic frequencies from bioactivated fluids of non human organisms to be used in bioresonance therapy and/or in therapeutic frequential solutions against diseases and/or pathogen infections in human organisms.

The method herein described is carried out by a bioresonance device. The bioresonance device can obtain, i.e. read, record, store, and reproduce electromagnetic frequencies from human and non-human organisms. The device is also able to combine the electromagnetic frequencies from natural bioactive compounds, already existing or previously stimulated in non-human organisms with electromagnetic frequencies of human organisms and returning the obtained immunological electromagnetic frequencies to the human organism. When exposed to the electromagnetic frequencies of a certain disease and/or pathogen, certain aquatic non-human organisms are able to develop an immunologic response in the form of electromagnetic frequencies that are obtained (i.e. read/measured and stored) by the bioresonance device. The electromagnetic frequencies related to said response can then be transferred directly to a human organism, or to a carrier to be administered to the human organism, such as a fluid or composed solution, in order to treat the human organism suffering from said disease and/or pathogen by means of bioresonance therapy.

For the purposes of the present invention, the efficiency of the present method was tested using a freshwater bivalve Anodonta cygnea in order to produce an immunologic response to SARSCoV infection, by means of in silico transference of viral electromagnetic frequencies into the bivalve organism using the Mora®Nova device.

With this methodology it is possible to obtain electromagnetic frequencies to treat a wide range of diseases and/or pathogen infections with a direct bioresonance device therapy or a therapeutic frequential composed solution or still a mixed bioactivated fluids with composed solution.

The example provided for the present method (Example 1) is a dynamic and functional approach based on in silico screening of human physiological behavior in normal and different experimental conditions.

The evaluations were combined with electromagnetic frequencies emitted through biological fluids of A. cygnea, supported by a computational integrator Mora®Nova device, to prove therapeutic efficacy. In fact, this therapeutic technique works like "shutting down" the pathological electromagnetic (EM) wave by a mirror inverted wave with "louder" EM resonance. Charged particles such as electrons and protons—create EM fields when they move, and these fields transport the type of energy we call electromagnetic radiation. This innovative therapeutic approach might be of high relevance to test because SARS-CoV virus envelope appears to consist of a distinctive pair of dense electron involucres. This can be experienced with or without SARSCoV infection and respective drastic functional effect in different human organ systems.

Therefore, according to the example provided, this method can constitute an innovated and expeditious way to assess the effectiveness of A. cygnea bivalve fluids, and other biological samples, due to a probable bioactive compound, against the SarsCov-virus strain or other subsequent mutant during human infection, or other diseases and/or pathogens.

In the example provided, the method combines the activated immunological bioactive compounds from the bivalve organic fluids (used as a non-human biological organism) with a computational integrator of MoradNova equipment in order to fight, under in silico essay, the SarsCov-virus infection in humans based on electromagnetic frequencies from virus and induced bivalve antibodies. Mora®Nova is a bioresonance integrator already recognized as a medical device by the European Community. According to several authors it is increasingly well accepted that the bioresonance electromagnetic frequency method offer a consistent diagnosis and therapy with promising results both on the human immune system and in mental disorders [10-14: Lekarski 1997; Nienhaus and Galle, 2006; Herrmann E and Galle 2011; Pihtili et al. 2014; Gramowski-VoB et al., 2015; Hong 2016; Karakos, et al., 2019). On the other hand, based on the device's bioresonance it is possible to receive, memorize, compose and emit frequencies of all single particles or complex compounds, solid or liquid matters as well as of living organisms like bacteria and virus.

The MORA®Nova bioresonance device allows to simulate, evaluate and adjust, in silico, the pharmacological potential of natural/biological compounds for specific and personalized human therapy in different diseases and/or pathologies, such as SARSCoV diseases as shown in the example.

The natural compound selected for the present example was the biological fluid (hemolymph and plasma) extracted from a freshwater bivalve to function as a dynamic interface between the human model and the computerized integrator during different functional evaluations in silico essays. The reason for choosing the bivalve fluids is supported on several experiences and scientific information revealing that this bivalve shows great potential and plasticity to cope and survive against extreme and aggressive conditions, as bacteria, noxious organic compounds, heavy metals and high hydrogen sulfide (H2S) too (Antunes et al., 2010; Lopes- Lima et al., 2012, Antunes et al., 2014) composing extreme toxic habitat. Thus, according to these findings, it is possible to point out A. cygnea fluid as an appropriate intermediator for searching and developing adequate immunological defense based on new bioactive molecules. This is still more expected since A. cygnea is a primitive animal with primary immune defense cells, granulocytes and hyalinocytes added of humoral factors with eventual large immunological plasticity (Antunes et al., 2010; Hinzmann et al., 2017; 2018; Hinzmann and Sousa 2020). All these properties and circumstances suggest the presence of robust defense cells in the hemolymph which can develop precursor molecules able to be modulated with adequate specificity against several virus strains.

Since there is a real concern regarding toxic agents on the basal human system that can induce a physiological intoxication, it was represented in the example by the toxic MEBES compound which can simulate accidental or chronic human disease additionally to virus infection in the same body.

With the example it was possible to evaluate the inherent immune plasticity of A. cygnea, and so to find out the own bio-natural compounds, in the hemolymph and plasma, able to counteract the development of the most recent aggressive SARSCov lineage viruses. To perform this operation an intelligent medicine integrator, Mora® Nova Equipment was used to diagnose the alterations of human normal physiological parameters in the presence of SARSCov infection as well as to induce an adequate amelioration through specific stimulation of bio-substances. Then, the immune efficacy of the hemolymph and plasma fluids was studied, with or not previous SARSCov impregnation and incubation, and tested against human infection. This involved in silico essays with MoraCNova emitting electromagnetic frequencies from both fluids into memorized human systems, infected or not with SARSCov virus. Subsequently, it was proposed to apply the electromagnetic frequencies of new SARS-stimulated immune-factors from bivalve fluids into virtual infected human body to reduce or eliminate the SARS-virus effects. Preliminary data (with efficacy of 95% in average) could preview to find an expeditious, functional and dynamic method to adjust the immune-system of A. cygnea fluids against SARS-virus lineage and respective mutants. Moreover, using the bioresonance devices such as the Mora®Nova device, human pathological fluids such as a drop of peripheric blood, mucus or saliva may also be screen, record and transferred as a frequential substance used to program a specific immune response in non human organisms. Preliminary tests made us predict a high specific and tailored treatment considering not only the virus strain but the individual biological terrain condition. This research study will be accomplished in near future under a clinical case, cellular and biomolecular/proteomic study program.

Based on the example disclosed below, it was possible to develop a method of obtaining electromagnetic frequencies from aquatic non-human organisms in view of being used as a bioresonance therapy and/or in therapeutic frequential solutions against diseases and/or pathogen infections in human organisms, comprising the following steps:

Obtaining electromagnetic frequencies related to at least one disease and/or at least one pathogen carried out by a bioresonance device;

In which the bioresonance device obtains (i.e. measures/reads or acquires from a data base) electromagnetic frequencies related to a disease and/or pathogen .

Obtaining a biological fluid sample from an aquatic non-human organism; In which at least one sample of a biological fluid is extracted from the aquatic non-human organism following laboratory procedures known in the art to a skilled person.

Transferring the electromagnetic frequencies related to at least one disease and/or at least one pathogen to the biological fluid sample using the bioresonance device;

In which the bioresonance device is used to transfer the electromagnetic frequencies obtained in the first step to the biological fluid sample to produce a bioactivated biological fluid sample.

Administering the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen (i.e. the bioactivated biological fluid sample) to an aquatic non-human organism such as to promote an immune response against the at least one disease and/or at least one pathogen by the aquatic non human organism;

In which said bioactivated biological fluid sample is administered to the aquatic non-human organism following laboratory procedures known in the art to a skilled person.

Obtaining a second sample of biological fluid sample from said aquatic non-human organism administered with the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen;

In which a second sample of biological fluid is extracted from the aquatic non-human organism following laboratory procedures known in the art to a skilled person.

Obtaining electromagnetic frequencies from the second sample of biological fluid of said non-human organism administered with the electromagnetic frequencies related to at least one disease and/or at least one pathogen using the bioresonance device.

In which the bioresonance device is used to obtain (i.e. measure/read and store) electromagnetic frequencies from the previous second sample of biological fluid.

Brief description of drawings

For easier understanding of this application, figures are attached in the annex that represent the preferred forms of implementation which nevertheless are not intended to limit the technique disclosed herein.

Figure 1 shows the several steps (A) of extraction, infection and manipulation of different organic bivalve fluids in order to evaluate the own specific immuno-defenses properties either or original form or virus treated form. The respective remaining fluids (B) were kept in refrigerator at -20°C for 2 weeks, after which they were checked again for immuno- defenses against SARSCOV-Virus in human infection.

Figure 2 shows the methodological scheme of all control and experimental groups using marine liquid and fluid extracted from freshwater bivalve of A. cygnea, followed by Cov- impregnation (with electromagnetic frequencies), Cov- incubation and refrigeration processes. Physiological parameters were evaluated with the bioresonance dedvice in the presence of different liquid/fluid conditions when simultaneously occurs or not human SARSCov-infestation too. This scheme reproduces all operative systems according to four conditional phases and six test reading periods.

Description of embodiments

Now, preferred embodiments of the present application will be described in detail with reference to the annexed drawings. However, they are not intended to limit the scope of this application.

The present invention relates to a method of obtaining electromagnetic frequencies from aquatic non-human organisms to be used in bioresonance therapy and/or in therapeutic frequential solutions against diseases and/or pathogen infections in human organisms.

The method of obtaining electromagnetic frequencies for bioresonance therapy and/or in therapeutic frequential solutions against a disease and/or pathogen comprising the following steps:

Obtaining electromagnetic frequencies related to at least one disease and/or at least one pathogen carried out by a bioresonance device;

Obtaining a biological fluid sample from an aquatic non-human organism;

Transferring the electromagnetic frequencies related to at least one disease and/or at least one pathogen to the biological fluid sample using the bioresonance device;

Administering the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen (i.e., a bioactivated biological fluid sample) to an aquatic non-human organism such as to promote an immune response against the at least one disease and/or at least one pathogen by the aquatic non human organism;

Obtaining a second sample of biological fluid sample from said aquatic non-human organism administered with the sample of biological fluid comprising the electromagnetic frequencies related to at least one disease and/or at least one pathogen;

Obtaining electromagnetic frequencies from the second sample of biological fluid of said non-human organism administered with the electromagnetic frequencies related to at least one disease and/or at least one pathogen using the bioresonance device.

The present method allows to obtain electromagnetic frequencies against disease and/or pathogens that can be transferred to a human organism using the bioresonance device or transferred to a physiological carrier using the bioresonance device.

In the context of the present invention, a carrier can be a physiological solution mixed with an aliquot of non-human fluid, or stimulated by a bioactivate compound frequency that can be administered to the human organism orally, sublingually, intravenously, transdermally, subcutaneously, intraperitoneally, or via a mucous membrane.

In one embodiment, the biological fluid is plasma, hemolymph, blood, or respective filtrates and a composed physiological solution.

In one embodiment, the electromagnetic frequencies related to at least one disease and/or at least one pathogen can be obtained from a human organism in which the disease and/or the pathogen is present.

In one embodiment, the electromagnetic frequencies related to at least one disease and/or at least one pathogen can be obtained from an electromagnetic frequency database.

In one embodiment, the aquatic non-human organism is a living organism such as a freshwater mollusk bivalve selected from, but not limited to, Anodonta cygnea, Anodonta anatine, Unio pictorum, Unio tumidus, Unio crassus, Margaritifera margaritifera , Hyriopsis myersiana, Hyriopsis cumingii, Pseudoanodonta complanate, Sinanodonta woodiana, Corbiculafluminea, Corbicula fluminalis, Corbicula elegans, Corbicula japonica, Corbicula africana.

In one embodiment, the aquatic non-human organism is a living organism such as a saltwater mollusk bivalve selected from, but not limited to, Crassostrea angulata, Crassostrea gigas, Crassostrea virginica, Mytilus edulis, Mytilus galloprovincialis , Mytilus platensis, Mytilus trossulus, Ruditapes decussatus, Ruditapes variegatus, Ruditapes philipinarum, Pinctada maxima, Pinctada Margaritifera, Pinctada fucata, Pinctada Martensi, Pecten maximus, Pecten jacobeus, Pecten yessoensis, Pecten novaezealandiae, Pectin ravenelim, Pecten tigris.

In one embodiment, the aquatic non-human organism is a living organism such as a freshwater or saltwater fish selected from, but not limited to, Mugil cephalus, Mugil curema, Mugil brasiliensis, Liza ramada, cyprinus carpio, Oncorhynchus mykiss, Salmo truta, Salmo lacustris, Trachurus trachurus, Trachurus picturatus, Scomber scombrus, Scomber colias, Scomber japonicus, Scomberomorus brasiliensis, Dicentrarchus labrax, Centropomus undecimalis, Solea solea ou solea vulgaris, Solea senegalensis, Platichthys flesus, Parallchthys braslllensls, Scophthalmus rhombus.

In one embodiment, the aquatic non-human organism is a living organism such as a crustacean selected from, but not limited to, Carcinus aestuarii,. Carcinus maenas, Scylla serrata, _· Cancer pagurus, Cancer productus , Cancer bellianus, Procambarus clarkii, Procambarus alleni or other species of Procambarus .

In one embodiment, the bioresonance device is selected from, but not limited to, MORA device, MoraONova device, Listen Machines, Bicom device, Sensitiv Audit and Imago device or Vega Select Machine.

In one embodiment, the disease is selected from, but not limited to, Pneumonia, COVID-19, Chronic rhinitis, Asthma, COPD - Chronic obstructive pulmonary disease, Chronic sinusitis, the flu, Pharyngitis, Acute bronchitis, ARDS - Acute Respiratory Distress Syndrome.

In one embodiment, the disease is a cancer selected from, but not limited to, Carcinomas, Sarcomas, Lymphomas, Leukemias, Melanoma.

In one embodiment, the disease is a neuro-development disorder selected from, but not limited to, an Autism spectrum disorder, Language disorder, Attention deficit disorder, Learning disorder, Hyperactivity. In one embodiment, the disease is an auto-immune disease selected from, but not limited to, Lupus, Rheumatoid arthritis, Crohn's disease, Vitiligo, Psoriasis, Type 1 diabetes, Multiple sclerosis, Celiac disease, Hashimoto's Thyroiditis, Sjogren's Syndrome.

In one embodiment, the disease is a neurodegenerative disease selected from, but not limited to, Alzheimer's disease and other dementias, Parkinson's disease (PD) and PD-related disorders, Transmissible spongiform encephalopathy, Motor neuron diseases, Huntington's Disease, Spinocerebellar Ataxia, Spinal Muscle Atrophy.

In one embodiment, the disease is a rare disease selected from, but not limited to, Gaucher disease, Hemophilia, Acromegaly, Hereditary angioedema.

In one embodiment, the disease is a metabolic disease selected from, but not limited to, Cholesterol problems - with risk of stroke and heart attack, Blood glucose changes, Snoring, Headache, Dizziness, Fatigue, Diabetes - with the development of the disease, Menstrual alteration - for women, Loss of libido - for men, Weight gain, Joint pains, High blood pressure.

In one embodiment, the pathogen is selected from, but not limited to, virus, bacteria, parasite or fungus.

In one embodiment, the pathogen is selected from, but not limited to, bacteria that causes tuberculosis, vaginosis, chlamydia, scarlet fever or leprosy. In one embodiment, the pathogen is selected from, but not limited to, a virus such as Corona virus, Zika, Ebola, Mumps, HPV, Measles.

In one embodiment, the pathogen is selected from, but not limited to, a fungus that causes candidiasis or mycoses.

In one embodiment, the pathogen is selected from, but not limited to, parasites that cause Chagas disease, leishmaniasis or toxoplasmosis.

The following example 1 was performed to prove the efficiency of the method disclosed above. A skilled person in the field would know how to provide variations of the teachings herein provided without departing from the spirit of the invention disclosed in the present patent application.

Example 1

Material and Methods

1) Mora®Nova Equipment - Physiological Parameters Evaluation

This equipment offers a quick, non-invasive screening method for determining health imbalances based on an "Energetic" assessment of the individual. The Energetic System knows the presence of every organism living in your body including all viruses, bacteria, fungi, and parasites as well as detect every toxin and every other factor that influences our state of health (Leonhardt, 1980).

MORA®Nova is a bioresonance evaluation technique, which can accomplish both diagnosis and therapeutics processes based on the findings of quantum physics and strongly supported on scientific basic principles from Dr. Voll ^' s Electroacupuncture (EAV) findings (Voll, 1975). All future work in silico evaluations of several physiological human parameters, as those from Lymphatic, Nervous, Circulatory, and endocrine (Allergy), systems, should be carried out in clinical case conditions with MoraCNova. This device is already considered a medical device with European Certification (CE) classe Ila, no. 414355 MR5, based on a computerized bioresonance instrument, manufactured by Med-Tronik GmbH Company in Friesenheim, Germany. Additional recent European Certification concerns DQS MED ISO 13485 (including software validation, sterility barrier systems, medical equipment files and contamination control. Testing technique and protocol will be followed according to manufacturer's standard for different substances and its conditional phases. This procedure is run selecting specific bioelectrical points (acupuncture points) and respective conducts (meridians) well distributed in the extracellular matrix of human body with functional, dynamic and fast transmission, mainly in feet and hands for a personal diagnosis (Voll, 1975; Pischinger, 2007; Colbert et al., 2008; Karakos, et al., 2019 Hong 2016).

2) Evaluation Study Design

This in silico method can be tested on different SARCov- virus strains or respective mutants with MORA®Nova to estimate its diagnostic, data assessment and memory facilities as well as defense versatility, effectiveness and quick adaptation of fluids properties. In addition, any bioresonance therapy can be supported on bioactive compound fluid previously modified or not with the respective viral frequencies .

Thus, a natural and biological product like that of organic fluids from A. cygnea bivalve was select to assess the real potential of own immune effect against SARSCov diseases. This evaluation was accomplished by in silico essays with several reading tests of human physiological parameters per group of human conditions and per different phases of bivalve fluids (hemolymph and plasma) or other natural liquid.

This can, for example, involve the individual to be connected to the Mora®Nova device by the electrodes interfacing or not with liquid medium at different phases for test values readings. In these different situations, the evaluation of human SARSCov virus infection was carried out when respective virus frequency memory was applied in silico by the Mora®Nova device into the human model. So, the physiological systemic outcomes to be consider in human are pulmonary, lymphatic, circulatory as the primary and gastrointestinal, cardiac, nervous, and endocrine (in specific allergy sensitivity) systems as the secondary.

In order to systematize all described procedures, an operative diagram is represented indicating four conditional phases and six reading periods where different human physiological results were obtained by bioresonance frequency waves from the human body and fluid or liquid substances, after being influenced or not by SARSCov-virus infection (Figures 1-2).

3) Bivalve Accommodation and Hemolymph Collection

Freshwater mussels, A. cygnea, were collected from the Mira Lagoon, Aveiro region in northern Portugal, transported in a refrigerated thermic box and transferred to large tanks (100 L) in the Aquatic Production Department of ICBAS- University of Porto. In order to stabilize the physiologic conditions a total of 54 bivalves should be acclimatize in freshwater tanks at 18°C with a recirculation system for 15 days. They will be fed by a normal diet with Chlorophyta microalgae (mainly chlorella strain). For collecting the organic fluid (hemolymph) the animals with healthy condition should close their valves when disturbed, showing active and powerful valve moving or water ejection upon disturbance (Antunes et al., 2014). The hemolymph extraction was accomplished, firstly by forcing to open the valves (1-2 cm) with a knife and inserting a cone tube of 1-1.5 cm to keep them separated. Then, the hemolymph was carefully removed with a 0.8x40 mm needle attached to a sterile 10-ml Hamilton syringe and inserted between the valves towards the mantle tissue (in anterior region of right or left valve), introducing and withdrawing slowly from the mantle intersticium (Antunes et al., 2014).

A total fluid volume around 5-10 ml was collected from 3 bivalves and mixed composing one fluid sample group and was be kept into Eppendorf tubes at 5°C in ice. This organic mixed fluid per group constituted a biologic sample average giving thus a physiological uniformity per sample group. For the substances test in the Mora apparatus, half of the fluid volume per group was centrifuged at 5.000 rpm (Sigma 3-16K) at 5°C during 15 min in order to also obtain a bivalve plasma. Then, the original hemolymph (H) and respective centrifuged plasma (P) from the same bivalves' group was kept at approximately 0°C in ice until to be use in each in silico essay for evaluating the physiological effects per human individual.

4) Identification of liquid sample groups and phases for testing as medium

The main objective of this example was to evaluate much the organic fluids (named Hemolymph-H and Plasma-P) from bivalves and modified liquid from the natural marine plasma (sea water prepared by Ibiza y Formentera Agua de Mar S.L.) can interfere protecting or damaging the basal-normal condition of human physiological parameters (human control) or the disease condition when infected with a SARSCovid strain (human experiment).

For this, an adequate operative sequence scheme (Figure 1- 2) is proposed for a better understanding of the whole procedure in different phases.

A simulation of SARSCoV attack against basal human functions was induced by an in-silico infection supported by Mora® Nova bioresonance frequency waves through respective virus memory frequency. Subsequently, a disturbance of the basal human conditions eventually occurs and will be observed.

Similarly, it will be done the substance tests using fluid/or liquid solutions as biological interface medium to evaluate the effects of own natural compounds on the human body when is present or not the SARS-virus infection.

In the next step, the fluids/liquids were in-silico impregnated with SARSCoV virus memory frequency by Mora®Nova transference following the respective reading test to access again the influence on physiological human values with or not SARS-virus infection.

Moreover, this impregnated hemolymph and plasma was after injected in bivalve foot or mantle, respectively on two sub groups of 3 bivalves each, in order to initiate hemolymph and plasma virus-incubation with bathing phase for two days (48 hours) in separated experimental tanks under the same acclimatization conditions.

In the next phase, from the incubated sub-groups the bivalve fluids were again extracted; the resultant fluids were mixed per sub-groups of 3 bivalves each and centrifuged to obtain the plasma and hemolymph (Figure 1). The new incubated plasma and hemolymph were again submitted to the same substance test sequence to assess the interference in the human control and in the infected experimental conditions by the SARSCov virus.

Based on this exposition it was possible to identify fluid efficacy in several conditions during phase I (Figure 1 and 2): organic bivalve fluids composed by the original hemolymph and plasma; bivalve original fluids impregnated by SARSCov- virus bioresonance frequency using the Mora®Nova device; original marine plasma as natural liquid (from the Ibiza y Formentera Agua de Mar S.L.) and impregnated marine plasma with virus bioresonance frequency were evaluate too.

After, a phase II started for evaluating the eventual efficacy of the hemolymph and plasma previously virus- incubated, being additionally combined or not with MEBES compound which can simulate high toxicity conditions like a chronic disease.

Phase III was accomplished with the main goal of studying the eventual immunological reaction induced by the bivalve's stress during fluid manipulation (extraction-injection- bathing-extraction) processes. Thus, 3 original bivalves were selected, from those already used at the beginning in the first extraction, in order to be injected with original remaining fluid (without any virus manipulation), followed by water bathing and extraction again.

Finally, Phase IV was carried out based on the tests with the different remaining refrigerated fluids, such as: the original-control fluids and marine plasma, experimental fluids and marine plasma submitted to SARSCov bioresonance impregnation and bivalve incubation bath as well as original fluids from the bivalve stressed condition with injection/extraction manipulations without any virus influence. After 2 weeks of refrigeration period all fluids/liquids were submitted again to similar test readings with the bioresonance equipment, under the same control and experimental human conditions, to evaluate the validity time of immunological defense reactions and properties in these fluids against virus infection.

Relatively to the bivalve incubation period (phase II), both bivalve sub-groups, one from injected hemolymph and other from injected plasma, under in silico virus-infection, were separately kept in two new tanks for bathing during 2 days with aerated water, room temperature (20-30°C) and with the same diet too. The water recirculation was stopped for avoiding the virus frequency contamination among experimental sub-groups and other control bivalves.

In order to accomplish a protocol study in the future it should be selected six voluntary human individuals under normal physiological conditions and nine bivalves per each individual which will complete a total of 54 bivalves in the end of experimental program.

Results: Functional Evaluation of Physiological Parameters After room acclimatization during phase I, a first operative and reading period with Mora®Nova evaluation consisted in the basal physiologic parameter evaluations in a human individual to set human basal conditions as a primary control data (CO) per each person (total of 6 individual cases).

Along the following phases, the human virtual infection of SARSCovid was evaluated alone or combined with the MEBES toxic compound frequency to potentiate the virus effect, thus simulating high internal body toxicity, when occurs for ex. occasional deep or chronic alterations in the human disease (comorbidity). The results from both mentioned human physiological conditions (control and experimental) were again evaluated with bio-interferences from marine liquid, bivalve hemolymph and plasma when they are or not impregnated and incubated by SARSCovid virus frequency.

So, just after CGO of human control evaluations, a second reading period starts to assess the bioresonance data from the interference on the human basal parameters induced by original hemolymph (H) and plasma (P) extracted from 3 A. cygnea bivalves and the modified marine liquid (ML). These readings represent the first liquid control data, respectively from (CG1H), (CG1P) and (CG1ML) liquid conditions, able to check their biological influences in human physiological parameters. After this, results concerning measurements of marine liquid/organic fluid interferences during the human SARSCovid infection, with or without MEBES toxic compound, accomplished the first experimental group conditions (EG1H, EG1P and EG1ML), showed in the Figure 2. This first essay period (control and experimental) proposes to demonstrate if both original liquid and bivalve fluids can interfere in human physiological parameters (normal or SARS virus infected) due to any natural defense factors combined or not with MEBES toxic compound (Figure 2). This will allow to have a general concept about the balance influence of natural and original compounds relatively to the infected or not human health.

In the next third reading period, the original marine liquid, hemolymph, and plasma were twice impregnated, during 2-3 min each, with in silico SARSCovid virus infection, amplifying at 40 times own frequency intensity by Mora bioresonance.

Just after, another experimental data during the second essay period (EG2H, EG2P and EG2ML) was obtained accomplishing similar readings without virus human infestation and followed by the third experimental period (EG3H, EG3P and EG3ML) on the virus infested human condition added or not with toxic MEBES (Figure 2). This offered the opportunity to evaluate the liquid/fluid immune properties induced by virus impregnation (contamination) and the respective immune capacity reducing the SARSCov infection in the human body.

Other conditional phase II concerning an experimental data during for fourth reading period with experimental fluids (EG4H, EG4P, EG5H, EG5P) extracted from the virus incubated hemolymph bivalves and experimental fluids (EG6H, EG6P, EG7H, EG7P) extracted from the virus incubated plasma bivalves was evaluated. The data expressed the bioresonance interferences of respective virus incubated hemolymph and plasma on physiological parameters without or with the in silico human SARSCovid infection, also alone or potentiated by MEBES toxic compound (Figure 2).

In the designated phase III, composed by fifth data readings, aimed to check the relevance of bivalve stress factor in the immune-physiological responses, due to the animal manipulations during fluid extraction, injection, incubation, and a new extraction. This reading period involved a control group of hemolymph and plasma (CG2H, CG2P) simply extracted at beginning from 3 original animals and a placebo group (sham-control - PG3H, PG3P) resulted from stress manipulation by injecting and incubating at water bath for 2 days followed by a new extraction, without any kind of virus contamination. The data evaluation of placebo manipulation effects against virus/MEBES human infection allowed to assess any natural defense properties of the hemolymph and plasma fluids after all mechanical-stress operations. This data was compared with those obtained from similar stress conditions and reading, but with previous SARSCov impregnation and incubation procedure (Figure 2).

At the final fourth condition, phase IV, several remaining original bivalve fluids (hemolymph and plasma) and natural marine plasma samples as well as the SARSCovid virus impregnated and incubated samples, were conserved during 2 weeks at -20°C in the refrigerator. After this period these samples will be submitted to a 6th reading period that aimed to verify if the respective immunological defense capacity of fluids/liquid, at different conditions, is maintained with refrigeration process against with human infested physiological parameters, combined or not with toxic MEBES compound. So, it will complete the evaluation of control (CG4H, CG4P), placebo (PG5H, PG5P) bivalve fluid groups and control marine liquid (CG2ML) as well as the experimental impregnated (EG8H, EG8P) and incubated (EG9H, EG9P) fluids and marine liquid groups (EG2ML), relatively to different bivalve hemolymph, plasma and marine plasma liquid conditions (Figure 2). In general, concerning the expected results it ^' s possible to preview a significant reduction of basic immune defenses in the human attacked by SARSCov infection and added to MEBES contamination. On the other hand, it ^' s also predictable that natural marine liquids or biological fluids from A. cygnea can eventually induce health amelioration changing slightly or deeply physiological parameters from virus infested human conditions. Moreover, particularly the biological fluids are complex fluids with cells and plasma rich in immune-factors, proteins and amino-acids offering high plasticity and dynamic reactions to the strange bodies, virus or bacteria (Ng, et al. 2015; Sousa and Mariana, 2020, Gestal et al., 2020, Carrol et al., 2021).

In fact, to simulate virus evasions in the human system it is possible with Mora integrator to induce in silico intervention by firing several virus biomagnetic frequencies and posteriori to evaluate the interference level and quality caused by biomagnetic frequencies emitted by natural liquids or biological fluids under original state. On the other hand, it will be expected more active and positive immuno-defenses with biological fluids of A. cygnea than with natural marine plasma as well as when these solutions are previously impregnated and incubated with SARSCov-virus. In fact, very preliminary and personal data already obtained predicted excellent and relevant results mainly with bivalve fluids from A.cygnea.

The bivalve fluids (hemolymph or plasma) impregnated and incubated with SARScov bioresonance frequencies showed clearly their biological immune-protection properties in the human systems against this virus lineage infestation. Based on excellent results, with efficacy of 95% in average, from the preliminary experiences of Example 1, it is possible to predict that this is an expert and efficient methodology to adopt as a functional and dynamic strategy to fight the diseases and/and pathogens. Furthermore, it can also complement other conventional therapeutic approaches and even help to reduce side-effects from some anti-viral drugs.

These in silico experiments when associated to the bioresonance frequencies from stimulated hemolymph compounds of the freshwater bivalve A. cygnea, leads to expect a high plasticity and immunological potential.

Obviously, additional in vitro studies in future, with adequate culture cell lineages in different conditions and with bioresonance treatment by MoraONova, should also be accomplished with hemolymph/plasma interference to confirm the pertinence, and the real efficacy on SARSCov infection as well as to clarify the respective biological mechanisms. In addition, to analyze and evaluate any specific bioactive compound from the induced hemolymph condition it needs molecular experiments which can give deep structural information concerning any efficient molecule against the SARSCovid virus lineage and respective mutants. Effectively, according to current scientific opinion, the virus mutation phenomenon leads to great and problematic difficulty for maintaining the collective and human global immunization. In this case, the present method offers a very functional, dynamic, and efficient process when combined with a biological non-human organism, as the bivalve A. cygnea, with high plasticity and eventual molecular reconstructive adaptation. This method can extend to other pathologies such as cancer, neurodevelopment and neurodegenerative and auto immune diseases as well as to explore easily the effects of other bio-compounds on similar diseases. To do so future cellular and biomolecular studies will be performed.

This description is of course not in any way restricted to the forms of implementation presented herein and any person with an average knowledge of the area can provide many possibilities for modification thereof without departing from the general idea as defined by the claims. The preferred forms of implementation described above can obviously be combined with each other. The following claims further define the preferred forms of implementation.